Last Updated: September 26, 2026
Meta Description: Learn how to audit prescriber rosters, build data pipelines, reconcile contract pharmacy statements, and capture missed 340B revenue. Step-by-step guide for covered entities.
Most covered entities leave 340B revenue on the table because prescriber rosters drift, contract pharmacy statements hide margin in trailing accounts receivable, and carve-out opportunities go unnoticed. Without visibility into your 340B pharmacy revenue analytics, you're managing blind.
In our experience, roughly one-third of active rendering providers go missing from TPA configurations because mid-levels render under a supervising NPI or the EHR carries the wrong identifier. When you can't match claims to the right provider, you lose eligibility visibility and audit readiness.
The fix is systematic: build a data pipeline, audit quarterly, read TPA statements on both cash and accrual bases, and track capture rates by drug class. This guide walks you through five steps to lock down your 340B pharmacy revenue analytics and find the leaks.
Your TPA prescriber configuration and your EHR claims report don't match. That mismatch costs you.
Pull your TPA's active prescriber roster and an EHR claims report filtered by rendering NPI for the last 90 days. Compare them line by line for:
When a prescriber isn't on the TPA roster or the NPI drifts between systems, claims don't route through 340B and the discount gets missed.
Action steps:
Do this reconciliation quarterly.
Drift happens when a provider changes EHR systems, a mid-level's supervising physician changes, an NPI updates in the EHR but not the TPA, or a new hire isn't added to the TPA roster. The result: claims route outside the 340B program.
In one audit, the clinic owner's own NPI was missing from the TPA roster, so their claims weren't getting the 340B discount.
How to spot drift:
Claims data lives in three places: your EHR, your TPA, and your payers. A data pipeline pulls all three sources into one place so you can see what's actually happening with your 340B pharmacy revenue analytics.
Run an EHR claims report with date of service, rendering NPI, drug/NDC, quantity, ingredient cost, payer, and claim status. Export as CSV. Pull the same from your TPA: submission date, drug/NDC, 340B ceiling price, reimbursement, withhold reserve movement, and carve-outs.
Merge the two datasets on date of service and NDC code to see what the EHR says was dispensed, what the TPA actually received, and where the gap is.
| Data Source | Key Fields | Update Frequency |
|---|---|---|
| EHR Claims | NPI, NDC, ingredient cost, payer, status | Daily |
| TPA Statement | Ceiling price, reimbursement, withhold, carve-outs | Monthly |
| Payer EOB | Allowed amount, paid amount, denial reason | As received |
Your payer mix determines how much 340B savings you keep. If you're a Florida covered entity with Medicaid patients, your Medicaid ID must be on the HRSA Medicaid Exclusion File. Medicaid claims carry Basis of Cost 08 and Submission Clarification Code 20, with ingredient cost capped at 340B ceiling price plus Florida's dispensing fee. Managed care encounters use SCC 20 and 9 per plan spec.
Your contract pharmacy's monthly statement is where revenue leakage hides. Most covered entities glance at it and file it away.
Your TPA statement shows two pictures: cash basis and accrual basis. They tell different stories.
Revenue leaks through carve-outs, margin held in reserve, and claims routed outside the program. Carve-outs are drugs you've agreed not to run through 340B, common for non-HIV generics where the pharmacy can't make margin or the payer reimburses below cost. Review net-per-claim by drug class; if a class runs negative, carve it out or move it to a different program modality.
| Issue | Impact | Fix |
|---|---|---|
| Prescriber not on TPA roster | Claim routes outside 340B, no discount | Update TPA roster immediately |
| Medicaid ID not on HRSA file | Medicaid claims ineligible | Verify status with HRSA OPA |
| Withhold reserve over 15% | Clinic margin held by pharmacy | Request quarterly true-up and release |
| Non-HIV generics running negative | Margin loss on high-volume drugs | Carve out or move to alternate modality |
Predictive analytics for 340B pharmacy revenue analytics means answering three questions: (1) Which patients are eligible? Build an eligible list from your EHR (STI positives, HPV, high-risk screening for PrEP; chronic conditions for primary care). (2) Which prescribers will write for them? Pull a 90-day claims report by prescriber and drug class. (3) What's your capture rate?
HRSA audits will ask for your prescriber roster, contract pharmacy agreement and reconciliations, sample claims showing eligibility and proper pricing, Medicaid Exclusion File status, and proof you're monitoring for duplicate discounts. Build a control calendar and assign an owner to each task.
The problem: A provider is hired, added to the EHR, and starts prescribing. But the TPA roster isn't updated. Their first month of claims routes outside the program.
The problem: Your Medicaid ID isn't on the HRSA Medicaid Exclusion File. Medicaid claims are eligible for 340B pricing, but they're being reimbursed at commercial rates.
The problem: The pharmacy is holding 20% of your margin in a withhold reserve. You're not seeing the cash for weeks.
The problem: Non-HIV generic drugs are running negative. You're losing money on every claim.
Optimizing 340B pharmacy revenue analytics is a quarterly discipline: audit your prescriber roster, build a data pipeline, reconcile contract pharmacy statements, track capture rates, and establish internal controls. Teams that do this consistently stay audit-ready.
Reconcile your TPA prescriber configuration against EHR claims data quarterly. In our experience, roughly one-third of active rendering providers can drift from the TPA config, mid-levels rendering under a supervising NPI, athena carrying the wrong NPI, or the owner missing entirely. Quarterly audits catch these gaps before HRSA audits do. List supervised providers under both their own NPI and the supervising provider's NPI to stay compliant.
Contract pharmacy economics drift silently. Most clinics read only the cash-basis cumulative ledger, which can show the clinic owing the pharmacy while accrual accounting shows the pharmacy holding clinic margin in trailing insurer A/R. Read both statements monthly. Also review net-per-claim by drug class; non-HIV generics often run negative and should be carved out or moved to a different program modality.
Florida Medicaid FFS pharmacy claims must carry Basis of Cost 08 and Submission Clarification Code 20. Your entity's Medicaid ID must be on the HRSA Medicaid Exclusion File. Ingredient cost should be capped at the 340B ceiling price plus Florida's dispensing fee. Managed care encounters use SCC 20 and 9 per plan specification. If claims are paying at full Medicaid rates, audit your TPA and pharmacy billing immediately.
Track capture rate (eligible prescriptions actually dispensed through 340B), transaction monitoring (claims routed correctly by payer and drug class), and margin by service line. Connect pharmacy analytics to your EHR and CRM so you can see which patients, providers, and service lines are generating the most defensible 340B revenue. Monthly reporting should show trends in eligible volume, carve-outs, and revenue per transaction.
Bring us your patient acquisition, 340B program, or compliance bottleneck. We will show you what a 30-day launch looks like for your clinic — in English or Spanish, month to month, no long contract.
